- Home
- Primary Care
- Phase 3 Evidence Supporting Finerenone in Diabetic Kidney Disease
2w3 min read
Medical Article
Introduction Diabetic kidney disease (DKD) is a common and serious complication of type 2 diabetes, contributing significantly to chronic kidney disease progression, end-stage kidney disease, and increased cardiovascular morbidity and mortality (1). Despite advances in standard-of-care therapies, including renin–angiotensin (RAS) inhibitors, SGLT2

Phase 3 Evidence Supporting Finerenone in Diabetic Kidney Disease
7 Reached
Similar Content

Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Catheter Ablation for Atrial Fibrillation with HF
691 Reached

Pancytopenia, a rare presentation of hyperthyroidism
832 Reached2 Comments

Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes
